Arkansas Methodist Medical Center (AMMC) is proud to introduce LEQEMBI (Lecanemab), a groundbreaking FDA-approved medication designed to slow the progression of Alzheimer's disease and improve the quality of life for patients and their caregivers.

LEQEMBI is an antibody therapy that targets the detrimental amyloid beta protein, associated with the formation of plaques in the brains of individuals with Alzheimer’s disease. In a marked advancement over previous treatments, LEQEMBI not only mitigates symptoms but also slows the progression of the disease itself by selectively binding to and clearing amyloid plaques from the brain.

"LEQEMBI is a significant step forward in Alzheimer's treatment, but it shouldn't detract from the importance of early detection and preventative measures," said Dr. Ron South, Neurologist at AMMC Neurology Associates. "Our comprehensive evaluation process helps us determine eligibility for LEQEMBI treatment, ensuring we can provide this innovative therapy to those who will benefit most."

AMMC is honored to be one of the select few institutions in Arkansas to offer a comprehensive LEQEMBI program, distinguishing itself as a leader in advanced Alzheimer's care within the region. This program emphasizes our dedication to not only enhancements in patient care but also hope and support to those dealing with Alzheimer’s, positioning AMMC at the forefront of neurological healthcare services.

LEQEMBI is administered through a patient-friendly outpatient infusion at AMMC. AMMC Outpatient Infusion Services stands out for its accessibility and convenience, offering patients a hassle-free experience from the moment they arrive. Unlike larger facilities, our center is designed with ease of access in mind. The stress-free parking and straightforward access to our services emphasizes our commitment to patient comfort and care, making the treatment process as smooth and worry-free as possible.

"We are proud to offer LEQEMBI as part of our commitment to providing the latest innovative treatments to our community and delivering exceptional care," said Dr. South. "Our goal is to improve the lives of those affected by Alzheimer's disease and offer hope for a brighter future."

"For patients in the LEQEMBI program, we are excited to offer a dedicated Dementia Coordinator, Jessica Nutt, APRN. This role is pivotal in providing continuity of care for all our patients," said Dr. South. "Jessica works closely with patients, families, and our team to ensure seamless communication and support throughout the treatment process. It's about more than just medicine; it's about comprehensive care for the individual."

Current patients of AMMC Neurology Associates are encouraged to discuss LEQEMBI with their provider during their next scheduled appointment. Those not currently under the care of AMMC Neurology Associates but wishing to be evaluated for Alzheimer's disease are asked to request a referral from their current provider to AMMC Neurology Associates. For more information on LEQEMBI and how to request a referral, visit the Neurology services page at www.myammc.org.